Praxis flouts phase 3 futility finding, forging ahead with tremor trial despite interim setback
Praxis Precision Medicines has been blindsided by a recommendation to stop a phase 3 essential tremor trial. Two months after Praxis CEO Marcio Souza said the chances of the trial being futile were “less than 3%,” the biotech has learnt the study looks unlikely to meet its primary endpoint at an interim analysis.
Praxis Precision Medicines has been blindsided by a recommendation to stop a phase 3 essential tremor trial. Two months after Praxis CEO Marcio Souza said the chances of the trial being futile were “less than 3%,” the biotech has learnt the study looks unlikely to meet its primary endpoint at an interim analysis.
